Erratum (DOI:10.1016/j.cardfail.2006.09.003);The Biologic Variability of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Stable Heart Failure Patients

Journal of Cardiac Failure

Volumn 13, Issue 1, 2007, Pages 50-55

  O'Hanlon, Rory ^a   O'Shea, Paula ^a   Ledwidge, Mark ^a   O'Loughlin, Christina ^a   Lange, Sophie ^a   Conlon, Carmel ^a   Phelan, Dermot ^a   Cunningham, Sean ^a   McDonald, Ken ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Chronic disease management; Clinical assessment; Heart failure drug titration; Intraindividual variability

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; BLOOD SAMPLING; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; COVARIANCE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; REVIEW; SEX RATIO; STATISTICAL ANALYSIS; SYSTOLIC HEART FAILURE;

EID: 33847267654     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.03.008     Document Type: Erratum

References (29)

1. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
2. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., and vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
3. Tsutamoto T., Wada A., Maeda K., Hisanaga T., Maeda Y., Fukai D., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
4. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
5. Uusimaa P., Ruskoaho H., Vuolteenaho O., Niemela M., Lumme J., Ikaheimo M., et al. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 69 (1999) 5-14
6. McCullough P.A., Nowak R.M., McCord J., Hollander J.E., Herrmann H.C., Steg P.G., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106 (2002) 416-422
7. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
8. Murdoch D.R., McDonagh T.A., Byrne J., Blue L., Farmer R., Morton J.J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
9. Beck-da-Silva L., de Bold A., Fraser M., Williams K., and Haddad H. BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 11 (2005) 248-253
10. Luther S.A., McCullough P.A., Havranek E.P., Rumsfeld J.S., Jones P.G., Heidenreich P.A., et al. The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail 11 (2005) 414-421
11. Sheth T., Parker T., Block A., Hall C., Adam A., Pfeffer M.A., et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 90 (2002) 496-500
12. Lewin J., Ledwidge M., O'Loughlin C., McNally C., and McDonald K. Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis?. Eur J Heart Fail 7 (2005) 953-957
13. Fraser C.G. Biological variation: from principles to practice (2006), AACC Press, Washington, DC
14. Wu A.H., Smith A., Wieczorek S., Mather J.F., Duncan B., White C.M., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
15. Bruins S., Fokkema M.R., Romer J.W., Dejongste M.J., van der Dijs F.P., van den Ouweland J.M., et al. High intra-individual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50 (2004) 2052-2058
16. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., and Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 40 (2002) 371-377
17. Vickery S., Price C.P., John R.I., Abbas N.A., Webb M.C., Kempson M.E., et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46 (2005) 610-620
18. Del Ry S., Giannessi D., and Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin Chem Lab Med 39 (2001) 446-450
19. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 19 (2001) 557-571
20. Clerico A., Iervasi G., Del Chicca M.G., Emdin M., Maffei S., Nannipieri M., et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 21 (1998) 170-179
21. Clerico A., Del Ry S., and Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 46 (2000) 1529-1534
22. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
23. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem 20 (1974) 1255-1270
24. Cotlove E., Harris E.K., and Williams G.Z. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. III. Physiological and medical implications. Clin Chem 16 (1970) 1028-1032
25. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls G., and Richards M. Plasma amino-terminal B-type natriuretic peptide measured by Elecsys 2010 assay in a trial of hormone-guided treatment for heart failure. Clin Chem 49 (2003) 1212-1215
26. Johnson W., Omland T., Hall C., Lucas C., Myking O.L., Collins C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
27. Kazanegra R., Cheng V., Garcia A., Krishnaswamy P., Gardetto N., Clopton P., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001) 21-29
28. Lee S.C., Stevens T.L., Sandberg S.M., Heublein D.M., Nelson S.M., Jougasaki M., et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 8 (2002) 149-154
29. Guo Y.F., and Stein P.K. Circadian rhythm in the cardiovascular system: chronocardiology. Am Heart J 145 (2003) 779-786